REVIEW QUESTIONS – CHAPTER 26
... When the body loses tolerance for its own antigens and attacks them, autoimmune disease results. Autoimmune disease results in cellular damage of the body by its own immune system; it is treated with immunosuppressive drugs. ...
... When the body loses tolerance for its own antigens and attacks them, autoimmune disease results. Autoimmune disease results in cellular damage of the body by its own immune system; it is treated with immunosuppressive drugs. ...
Natural Defense Mechanisms
... Monocytes : Become Macrophages when they leave the blood and enter the tissues. Neutrophils: (Phagocytic cells) Eosinophils: (Allergy and Parasitic infections) Natural Killer (NK) cells: (Kill tumor cells and virus infected cells) (Cytotoxic cells work as natural killer) ...
... Monocytes : Become Macrophages when they leave the blood and enter the tissues. Neutrophils: (Phagocytic cells) Eosinophils: (Allergy and Parasitic infections) Natural Killer (NK) cells: (Kill tumor cells and virus infected cells) (Cytotoxic cells work as natural killer) ...
Systemic Lupus Erythematosus
... X-rays to detect fluid in chest and lungs Urinalysis to check protein levels in urine ...
... X-rays to detect fluid in chest and lungs Urinalysis to check protein levels in urine ...
Specific Immunity POGIL
... d=38635 and answer the following questions) The Facts on HIV/AIDS AIDS (acquired immune deficiency syndrome) was first recognized in North America in the early 1980s. It is caused by a virus known as HIV (human immunodeficiency virus). HIV infection has become a worldwide epidemic. About 33 million ...
... d=38635 and answer the following questions) The Facts on HIV/AIDS AIDS (acquired immune deficiency syndrome) was first recognized in North America in the early 1980s. It is caused by a virus known as HIV (human immunodeficiency virus). HIV infection has become a worldwide epidemic. About 33 million ...
Chapter 43 – Immune System
... 11. What is the role of cytotoxic T cells and describe their mechanism of action? ...
... 11. What is the role of cytotoxic T cells and describe their mechanism of action? ...
B cell activation and antibody production
... Distinct B cell subsets mediates different types of antibody responses ...
... Distinct B cell subsets mediates different types of antibody responses ...
NanoBots to Fight Cancer
... The $144.5 million plan will include the NCI Alliance for Nanotechnology in Cancer, an initiative to team up researchers, physicians, companies and not-for-profit groups to develop nanotechnology products for use in diagnosing and treating cancer. Medicine already employs molecular size devices in t ...
... The $144.5 million plan will include the NCI Alliance for Nanotechnology in Cancer, an initiative to team up researchers, physicians, companies and not-for-profit groups to develop nanotechnology products for use in diagnosing and treating cancer. Medicine already employs molecular size devices in t ...
THE IMMUNE SYSTEM
... substance capable of triggering an immune response is known as an antigen. • An antigen can be a whole non-self cell, a bacterium, or a virus. ...
... substance capable of triggering an immune response is known as an antigen. • An antigen can be a whole non-self cell, a bacterium, or a virus. ...
Document
... Saponins are derived from the bark of a Chilean tree, Quillaja sponaria, so unlike other immunostimulatory adjuvants, is not pathogen derived. A highly purified fraction called QS21 is a potent adjuvant for the induction of a Th1-dominated response, including CTLs. Saponins are thought to form pores ...
... Saponins are derived from the bark of a Chilean tree, Quillaja sponaria, so unlike other immunostimulatory adjuvants, is not pathogen derived. A highly purified fraction called QS21 is a potent adjuvant for the induction of a Th1-dominated response, including CTLs. Saponins are thought to form pores ...
Presentation slides - Yale School of Medicine
... • most efficient of all APCs • high MHC class I, II & costimulators • efficient cross presentation • stimulate naïve T cells (CD4, CD8) initiate Ag-specific immune responses ...
... • most efficient of all APCs • high MHC class I, II & costimulators • efficient cross presentation • stimulate naïve T cells (CD4, CD8) initiate Ag-specific immune responses ...
DEFINING HYPERSENSITIVITY
... Anaphylaxis: Prior sensitization has resulted in an immune response initially mediated by CD4 lymphocytes (of the Th2 variety) that promote mast cell proliferation and plasma cell production of IgE. The IgE becomes bound to mast cells in places such as respiratory tract mucosa. Encountering the alle ...
... Anaphylaxis: Prior sensitization has resulted in an immune response initially mediated by CD4 lymphocytes (of the Th2 variety) that promote mast cell proliferation and plasma cell production of IgE. The IgE becomes bound to mast cells in places such as respiratory tract mucosa. Encountering the alle ...
presentation
... viruses, killing bacteria, etc. T cells are also another helpful resource to the immune system. ...
... viruses, killing bacteria, etc. T cells are also another helpful resource to the immune system. ...
Immunobiology
... spleen, MALT, GALT and SALT; pattern recognition receptors. (b) Mechanisms of pathogen killing by macrophages and neutrophils. (c) Complement system: Components of the complement activation classical, alternative and lectin pathways; biological consequence of complement activation, methods to study ...
... spleen, MALT, GALT and SALT; pattern recognition receptors. (b) Mechanisms of pathogen killing by macrophages and neutrophils. (c) Complement system: Components of the complement activation classical, alternative and lectin pathways; biological consequence of complement activation, methods to study ...
Lecture 5 - Andrew.cmu.edu
... Antibody-Antigen Interactions. A specific complex forms between the antigen and the antibody. This complex is stabilized by complementary interactions between the antigen and amino acid residues from the antibody. One, or more, of the following interactions can stabilize the complex: i) Hydropho ...
... Antibody-Antigen Interactions. A specific complex forms between the antigen and the antibody. This complex is stabilized by complementary interactions between the antigen and amino acid residues from the antibody. One, or more, of the following interactions can stabilize the complex: i) Hydropho ...
The Immune System
... T cell receptors bind to antigens on antigen presenting cells (AHCs) on their major histocompatibilty complex molecules (MHCs). MHCs: proteins that are the product of gene groups. Class I MHCs are on all body cells except for red blood cells. Class II MHCs are made by B cells, macrophages, and dendr ...
... T cell receptors bind to antigens on antigen presenting cells (AHCs) on their major histocompatibilty complex molecules (MHCs). MHCs: proteins that are the product of gene groups. Class I MHCs are on all body cells except for red blood cells. Class II MHCs are made by B cells, macrophages, and dendr ...
The Human Immune System PPT
... - Your body has been exposed to the antigen in the past either through: - Exposure to the actual disease causing antigen – You fought it, you won, you remember it - Planned exposure to a form of the antigen that has been killed or weakened – You detected it, eliminated it, and remember it ...
... - Your body has been exposed to the antigen in the past either through: - Exposure to the actual disease causing antigen – You fought it, you won, you remember it - Planned exposure to a form of the antigen that has been killed or weakened – You detected it, eliminated it, and remember it ...
Matching – Each question is worth 0.5 pt
... Complete the following Diagram of B Cell DNA Gene rearrangement (4 pts) The final Mature B cell will display IgA1 immunoglobulin with V3D1J2 specificity. How many individual rearrangement steps will be required to produce this heavy chain? ...
... Complete the following Diagram of B Cell DNA Gene rearrangement (4 pts) The final Mature B cell will display IgA1 immunoglobulin with V3D1J2 specificity. How many individual rearrangement steps will be required to produce this heavy chain? ...
MICROBIO320 Short Answers – These should be typically 1
... All of the above. Which of the following statements is INCORRECT concerning antigen-specific receptors on B cells? (0.5 pt) A. They are clonally distributed transmembrane molecules. B. They have extensive cytoplasmic domains that interact with intracellular molecules. C. They consist of polypeptides ...
... All of the above. Which of the following statements is INCORRECT concerning antigen-specific receptors on B cells? (0.5 pt) A. They are clonally distributed transmembrane molecules. B. They have extensive cytoplasmic domains that interact with intracellular molecules. C. They consist of polypeptides ...
Assessment of immune function.Management of patients with im
... – Mechanical removal (coughing, vomiting, diarrhea, skin sloughing) – Normal flora – Antimicrobial secretions ...
... – Mechanical removal (coughing, vomiting, diarrhea, skin sloughing) – Normal flora – Antimicrobial secretions ...
Immunology Immune Response
... IgA represents 10 to 15% of the total circulatory immunoglobulin pool. IgA predominates in body secretions and is mainly concerned with defending the exposed external surfaces of the body. It is found in the secretions of saliva, tears, nasal fluids, colostrums breast milk, sweat, genito-urinary and ...
... IgA represents 10 to 15% of the total circulatory immunoglobulin pool. IgA predominates in body secretions and is mainly concerned with defending the exposed external surfaces of the body. It is found in the secretions of saliva, tears, nasal fluids, colostrums breast milk, sweat, genito-urinary and ...
Cancer immunotherapy
Cancer immunotherapy (immuno-oncology) is the use of the immune system to treat cancer. Immunotherapies fall into three main groups: cellular, antibody and cytokine. They exploit the fact that cancer cells often have subtly different molecules on their surface that can be detected by the immune system. These molecules, known as cancer antigens, are most commonly proteins, but also include molecules such as carbohydrates. Immunotherapy is used to provoke the immune system into attacking the tumor cells by using these antigens as targets.Antibody therapies are the most successful immunotherapy, treating a wide range of cancers. Antibodies are proteins produced by the immune system that bind to a target antigen on the cell surface. In normal physiology the immune system uses them to fight pathogens. Each antibody is specific to one or a few proteins. Those that bind to cancer antigens are used to treat cancer. Cell surface receptors are common targets for antibody therapies and include the CD20, CD274, and CD279. Once bound to a cancer antigen, antibodies can induce antibody-dependent cell-mediated cytotoxicity, activate the complement system, or prevent a receptor from interacting with its ligand, all of which can lead to cell death. Multiple antibodies are approved to treat cancer, including Alemtuzumab, Ipilimumab, Nivolumab, Ofatumumab, and Rituximab.Cellular therapies, also known as cancer vaccines, usually involve the removal of immune cells from the blood or from a tumor. Immune cells specific for the tumor are activated, cultured and returned to the patient where the immune cells attack the cancer. Cell types that can be used in this way are natural killer cells, lymphokine-activated killer cells, cytotoxic T cells and dendritic cells. The only cell-based therapy approved in the US is Dendreon's Provenge, for the treatment of prostate cancer.Interleukin-2 and interferon-α are examples of cytokines, proteins that regulate and coordinate the behaviour of the immune system. They have the ability to enhance anti-tumor activity and thus can be used as cancer treatments. Interferon-α is used in the treatment of hairy-cell leukaemia, AIDS-related Kaposi's sarcoma, follicular lymphoma, chronic myeloid leukaemia and malignant melanoma. Interleukin-2 is used in the treatment of malignant melanoma and renal cell carcinoma.